{
    "2021-02-03": [
        [
            {
                "time": "",
                "original_text": "安图生物大宗交易成交507.30万元",
                "features": {
                    "keywords": [
                        "安图生物",
                        "大宗交易",
                        "成交",
                        "507.30万元"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "安图生物今日大宗交易成交3.80万股，成交价133.5元溢价0.0%",
                "features": {
                    "keywords": [
                        "安图生物",
                        "大宗交易",
                        "成交",
                        "3.80万股",
                        "133.5元",
                        "溢价",
                        "0.0%"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药生物2月月报：寻业绩主线 重点关CXO等高增长赛道",
                "features": {
                    "keywords": [
                        "医药生物",
                        "2月月报",
                        "业绩主线",
                        "CXO",
                        "高增长赛道"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "CXO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}